What is HPT Pharma?
Based in the United States, HPT Pharma operates as a critical provider of blister packaging tooling and precision engineering solutions. With a legacy spanning over 25 years, the company serves a diverse clientele, including pharmaceutical manufacturers, contract packaging organizations, and clinical trial entities. Their core competency lies in the design and fabrication of high-precision blister tooling, supported by advanced in-house CNC machining capabilities. This technical proficiency allows HPT Pharma to maintain a competitive edge by offering significantly reduced lead times and cost-effective, high-quality packaging solutions that meet the rigorous standards of the global healthcare industry.
How much funding has HPT Pharma raised?
HPT Pharma has raised a total of $932K across 2 funding rounds:
Debt
$350K
Debt
$582K
Debt (2020): $350K with participation from PPP
Debt (2021): $582K led by PPP
Key Investors in HPT Pharma
PPP
Public-Private Partnership
What's next for HPT Pharma?
With the successful acquisition of $582K, HPT Pharma is well-positioned to accelerate its growth trajectory and expand its footprint in the pharmaceutical and nutraceutical packaging markets. The company is expected to prioritize the modernization of its manufacturing facilities and the further integration of automated CNC technologies to meet increasing demand for rapid-turnaround packaging solutions. As the industry faces heightened pressure for supply chain resilience, HPT Pharma's strategic focus on engineering excellence and operational agility will likely serve as a primary driver for long-term value creation and market leadership.
See full HPT Pharma company page
